Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen
International Journal of Neonatal Screening · 24.02.2025 · 11 (1) · 16
DOI: 10.3390/ijns11010016 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 24.02.2025. Verfasst von Hayley A Ron und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hackensack University Medical Center at Hackensack Meridian Health, Hackensack, NJ 07601, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pennsylvania started newborn screening for Pompe disease (PD) in 2016. As a result, the prevalence of PD has increased with early detection, primarily of late-onset Pompe disease (LOPD). No clear guidelines exist regarding if and when to initiate enzyme replacement therapy (ERT) in patients identified through a newborn screen (NBS). To help define the natural history and indications for starting ERT, we present the long-term follow-up data of 45 patients identified through NBS from 2016 to 2021. These patients were evaluated at regular intervals through our multi-disciplinary clinic at the Children’s Hospital of Philadelphia (CHOP) with physical examinations, physical therapy evaluations, muscle biomarkers including creatine kinase (CK), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and hexosaminidase 4 levels (Hex4), as well as cardiac evaluation at certain points in time. We found that newborn screening of acid alpha-glucosidase (GAA) enzyme detected primarily LOPD. One case of infantile-onset PD (IOPD) was detected. Muscle biomarkers in LOPD were elevated at birth and showed a general downward trend over time. NBS GAA levels and initial CK levels helped to differentiate LOPD cases from unaffected infants (carriers, pseudodeficiency alleles), while Hex4 was not a meaningful discriminator. On repeat NBS, there was a significant difference between mean GAA levels for the unaffected vs. compound heterozygote groups and unaffected vs. homozygote groups for the common splice site pathogenic variant (c.-32-13T>G). Echocardiogram and electrocardiogram (EKG) are essentially normal at the first evaluation in LOPD. One LOPD patient was started on ERT at age 4.5 months. Continued data collection on these patients is critical for developing management guidelines, including timing of ERT and improved genotype–phenotype correlation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hackensack University Medical Center at Hackensack Meridian Health, Hackensack, NJ 07601, USA.
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Cone Health, Greensboro, NC 27401, USA.
- Section of Biochemical Genetics, Division of Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Caitlin Menello, Nicole Engelhardt, Can Ficicioglu
Zitieren
APA
Ron, H. A., Kane, O., Guo, R., Menello, C., Engelhardt, N., Pressley, S., DiBoscio, B., Steffensen, M., Cuddapah, S., Ng, K., Ficicioglu, C., & Ahrens-Nicklas, R. C. (2025). Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen. International Journal of Neonatal Screening, 11(1), 16. https://doi.org/10.3390/ijns11010016
Vancouver
Ron HA, Kane O, Guo R, Menello C, Engelhardt N, Pressley S, et al. Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen. International Journal of Neonatal Screening. 2025;11(1):16. doi:10.3390/ijns11010016
BibTeX
@article{Ron2025,
author = {Ron, Hayley A and Kane, Owen and Guo, Rose and Menello, Caitlin and Engelhardt, Nicole and Pressley, Shaney and DiBoscio, Brenda and Steffensen, Madeline and Cuddapah, Sanmati and Ng, Kim and Ficicioglu, Can and Ahrens-Nicklas, Rebecca C},
title = {Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen},
journal = {International Journal of Neonatal Screening},
year = {2025},
volume = {11},
number = {1},
pages = {16},
doi = {10.3390/ijns11010016}
}
EUVIMED